Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019616 | 0.99 | ALDH1A1 (0.77) | ALDH1A1TSHRGAANPSR1ALOX15 | |
| SCHEMBL24019584 | 0.95 | ALDH1A1 (0.70) | ALDH1A1TSHRNPSR1ALOX15HTT | |
| SCHEMBL25609885 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TSHRGAANPSR1HTT | |
| SCHEMBL25609751 | 0.84 | HPGD (0.58) | ALDH1A1TSHRGAANPSR1HPGD | |
| SCHEMBL24019617 | 0.81 | NPSR1 (0.71) | ALDH1A1NPSR1HPGDCYP2C19MEN1 | |
| SCHEMBL24209779 | 0.80 | KMT2A (0.76) | ALDH1A1GAANPSR1HPGDCYP2C19 | |
| SCHEMBL24209903 | 0.79 | NPSR1 (0.68) | ALDH1A1NPSR1HPGDCYP2C19MEN1 | |
| SCHEMBL21952044 | 0.78 | MAPT (0.56) | ALDH1A1TSHRGAANPSR1HPGD | |
| SCHEMBL24209750 | 0.78 | ALDH1A1 (0.71) | ALDH1A1TSHRNPSR1HPGDKMT2A | |
| SCHEMBL24210125 | 0.78 | ALDH1A1 (0.71) | ALDH1A1TSHRNPSR1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | ALDH1A1 1206/4885TSHR 4635/4885GAA 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.